Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29

Impact · against what's priced in

The upcoming Merck Q3 results are a high-risk event where strong product launches (LIPFENDRA, QLEX) may only offset existing analyst pessimism and headwind expectations. Moderna remains positively impacted by Phase 3 melanoma results, though the market has already aggressively bid up the oncology platform's validation.

MRNA+0.05: Already priced in
The price assumes: The successful Phase 3 INTerpath-001 melanoma trial results and the validation of the mRNA oncology platform

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29

What matters in this story

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29

What matters in this story

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

How each ticker is affected

Connected tickers

Track these names every morning.

3 Massive Catalysts That Could Ignite an Eli Lilly Stock Rally on Oct 29

I Said Palantir Stock Would Top $220 This Year. Here's What It Has to Prove on Nov. 2.

Newmont's Record Quarter Shows Why Gold's Floor Is the Real Story

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29

What matters in this story

Next reads from the same story arc

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29

What matters in this story

Next reads from the same story arc

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

How each ticker is affected

Connected tickers

Track these names every morning.

3 Massive Catalysts That Could Ignite an Eli Lilly Stock Rally on Oct 29

I Said Palantir Stock Would Top $220 This Year. Here's What It Has to Prove on Nov. 2.

Newmont's Record Quarter Shows Why Gold's Floor Is the Real Story

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts